Gantenerumab
- Generic Name
- Gantenerumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1043556-46-2
- Unique Ingredient Identifier
- 4DF060P933
- Background
Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs). As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and aggregation to form NFTs and c...
- Associated Conditions
- -
- Associated Therapies
- -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 73
- Registration Number
- NCT06424236
- Locations
- 🇫🇷
Hopital Roger Salengro - CHU Lille, Lille, Nord, France
🇦🇺Neuroscience Research Australia, Randwick, New South Wales, Australia
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 25
- Registration Number
- NCT05256134
- Locations
- 🇺🇸
Visionary Investigators Network - Neurology Aventura, Aventura, Florida, United States
🇺🇸Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States
🇺🇸Premiere Research Institute, West Palm Beach, Florida, United States
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 194
- Registration Number
- NCT04623242
- Locations
- 🇺🇸
University of California San Diego Medical Center, La Jolla, California, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸Columbia University, New York, New York, United States
A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 192
- Registration Number
- NCT04592341
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇵🇱Senior Sp. Z O.O. Poradnia Psychogeriatryczna, Sopot, Poland
🇫🇷Gerontopole; Centre de Recherche clinique, Toulouse, France
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1382
- Registration Number
- NCT04374253
- Locations
- 🇺🇸
Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States
🇺🇸Brain Matters Research, Inc., Delray Beach, Florida, United States
🇺🇸Infinity Clinical Research, LLC, Sunrise, Florida, United States
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 116
- Registration Number
- NCT04339413
- Locations
- 🇦🇷
Instituto Neurologia Bs As, Ciudad Autonoma Buenos Aires, Argentina
🇯🇵Juntendo University Urayasu Hospital; Neurology, Chiba, Japan
🇵🇱NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek, Pozna?, Poland
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 975
- Registration Number
- NCT03443973
- Locations
- 🇺🇸
Irvine Center for Clinical Research, Irvine, California, United States
🇺🇸SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Texas Neurology PA, Dallas, Texas, United States
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1053
- Registration Number
- NCT03444870
- Locations
- 🇺🇸
Bradenton Research Center, Bradenton, Florida, United States
🇺🇸Neurology Consultants of Dallas; Research Department, Dallas, Texas, United States
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT03236844
- Locations
- 🇺🇸
PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States
🇺🇸PRA, Marlton, New Jersey, United States
🇺🇸PRA Health Sciences, Salt Lake City, Utah, United States
A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT02882009
- Locations
- 🇺🇸
PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.